K. Ross

发表

The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

Paul A Clemons, Aravind Subramanian, Steven A Carr, 2006, Science.

Gene expression correlates of clinical prostate cancer behavior.

E. Lander, T. Golub, P. Tamayo, 2002, Cancer cell.

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Todd, J. Mesirov, E. Lander, 2002, Nature Medicine.

A method for high-throughput gene expression signature analysis

T. Golub, J. Lamb, E. Crawford, 2006, Genome Biology.

A molecular signature of metastasis in primary solid tumors

E. Lander, T. Golub, K. Ross, 2003, Nature Genetics.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

T. Golub, K. Ross, P. Febbo, 2006, Cancer research.

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

T. Golub, W. Hahn, J. Lamb, 2006, Cancer cell.

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines

T. Golub, P. Tamayo, K. Ross, 2016, Nature Biotechnology.

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

T. Golub, K. Ross, K. Stegmaier, 2005, Blood.

Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Giovanni Roti, Lynn VerPlank, Nicola Tolliday, 2013, Chemistry & biology.

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras.

K. Ross, S. Armstrong, R. Koche, 2018, Blood advances.

Proteomic and genetic approaches identify Syk as an AML target.

Tina N. Davis, Steven A Carr, William C Hahn, 2009, Cancer cell.

REDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors

K. Ross, S. Ramaswamy, M. Mino‐Kenudson, 2020, Genes & development.

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

K. Ross, S. Armstrong, Heather J. Lee, 2019, Cancer cell.

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

K. Ross, K. Stegmaier, N. Gray, 2014, Oncotarget.

Geﬁtinib induces myeloid differentiation of acute myeloid leukemia

T. Golub, K. Ross, K. Stegmaier, 2005 .

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

Ansuman T. Satpathy, K. Ross, Michal Sheffer, 2022, Nature Cancer.

Digital Commons@Becker Digital Commons@Becker SIRT6 is required for normal retinal function SIRT6 is required for normal retinal function

K. Ross, S. Ramaswamy, R. Mostoslavsky, 2022 .

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

K. Ross, S. Ramaswamy, M. Lawrence, 2021, Clinical Cancer Research.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Gabriela Alexe, Giovanni Roti, Nicola Tolliday, 2012, The Journal of clinical investigation.

Identification of prostate cancer modifier pathways using parental strain expression mapping

Todd R Golub, William R Sellers, Massimo Loda, 2007, Proceedings of the National Academy of Sciences.

Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers

K. Ross, S. Ramaswamy, M. Lawrence, 2020, Science Advances.

Aneuploidy and deregulated DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers

K. Ross, S. Ramaswamy, M. Lawrence, 2019, bioRxiv.

Transcriptional control of autophagy–lysosome function drives pancreatic cancer metabolism

K. Ross, S. Ramaswamy, G. Stephanopoulos, 2015, Nature.

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

T. Golub, K. Ross, S. Haggarty, 2010, Proceedings of the National Academy of Sciences.

Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.

N. Perrimon, K. Ross, J. Aster, 2013, Cancer cell.

Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.

K. Ross, A. Niemierko, A. Bardia, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors

K. Ross, J. Aster, K. Stegmaier, 2010, PloS one.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

K. Ross, S. Ramaswamy, Kwok-Kin Wong, 2014, Nature.

The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine

K. Ross, S. Ramaswamy, K. Hochedlinger, 2015, Nature Cell Biology.

Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma

Todd R Golub, Kimberly Stegmaier, Andrew L Kung, 2007, PLoS medicine.

SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b

K. Ross, S. Ramaswamy, M. Rivera, 2016, Cell.

LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors

John T. Powers, R. Young, K. Ross, 2020, Proceedings of the National Academy of Sciences.

The Histone Deacetylase SIRT6 Restrains Transcription Elongation via Promoter-Proximal Pausing.

K. Ross, S. Ramaswamy, R. Sadreyev, 2019, Molecular cell.

High-throughput gene expression profiling of memory differentiation in primary human T cells

K. Ross, K. Stegmaier, W. Haining, 2008, BMC Immunology.

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation

Todd R Golub, Kimberly Stegmaier, Andrew L Kung, 2008, Proceedings of the National Academy of Sciences.

Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation

Todd R Golub, Brent R Stockwell, Kimberly Stegmaier, 2004, Nature Genetics.

Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies

K. Ross, A. Look, J. Aster, 2019, PLoS genetics.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

G. Getz, K. Ross, S. Ramaswamy, 2015, Nature Communications.

The ETS transcription factor ETV6 constrains the transcriptional activity of EWS–FLI to promote Ewing sarcoma

K. Ross, M. Rivera, Diana Lu, 2023, Nature Cell Biology.

Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance.

T. Golub, K. Ross, C. Ladd, 2002, Diabetes.

A unique subset of glycolytic tumor propagating cells drives squamous cell carcinoma

N. Hacohen, K. Ross, I. Tirosh, 2021, Nature Metabolism.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer

Ben S. Wittner, B. Wittner, K. Ross, 2017, Oncotarget.

Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.

Kenneth N Ross, K. Ross, S. Balk, 2006, Cancer research.

Post-transcriptional Increases in Cyclin D Proteins through Mammalian Target of Rapamycin Activation and Androgens Induce Prostate Cancer Cell Proliferation

K. Ross, S. Balk, Shaoyong Chen, 2006 .

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

K. Ross, M. Gönen, J. Bradner, 2010, The Journal of clinical investigation.

AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth

K. Ross, S. Ramaswamy, M. Loda, 2017, Molecular Cancer Therapeutics.

Integrin β1 activation induces an anti-melanoma host response

K. Ross, S. Ramaswamy, X. Solé, 2017, PloS one.

Identification of AML1-ETO modulators by chemical genomics.

T. Golub, K. Ross, K. Stegmaier, 2009, Blood.

A HIF1-alpha Regulatory Loop Links Hypoxiaand Mitochondrial Signals in Pheochromocytomas

Andrew L. Kung, Sandro Santagata, James F. Powers, 2005 .

suz12 inactivation in p53- and nf1-deficient zebrafish accelerates the onset of malignant peripheral nerve sheath tumors and expands the spectrum of tumor types

K. Ross, A. Look, J. Aster, 2020, Disease Models & Mechanisms.

suz12 inactivation in p53 and nf1 deficient zebrafish accelerates the onset of MPNSTs and expands the spectrum of tumor types to include adenocarcinoma, leukemia, and soft tissue sarcoma.

K. Ross, A. Look, J. Aster, 2020, Disease models & mechanisms.

Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation

T. Golub, K. Ross, B. Stockwell, 2004, Nature Genetics.

Light Controlled Modulation of Gene Expression by Chemical Optoepigenetic Probes

J. A. Hendricks, J. Lamb, K. Ross, 2016, Nature chemical biology.

SIRT6 Is Required for Normal Retinal Function

K. Ross, S. Ramaswamy, R. Mostoslavsky, 2014, PloS one.

AKT Inhibition Promotes Nonautonomous Cancer Cell Survival

K. Ross, S. Ramaswamy, X. Solé, 2015, Molecular Cancer Therapeutics.

SYK Regulates mTOR Signaling in AML

K. Ross, K. Stegmaier, D. DeAngelo, 2013, Leukemia.

Transcriptional control of the autophagy-lysosome system in pancreatic cancer

K. Ross, S. Ramaswamy, G. Stephanopoulos, 2015, Nature.

ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.

Sridhar Ramaswamy, Hongmei Mou, Jayaraj Rajagopal, 2017, Cancer cell.

HSP 90 is a therapeutic target in JAK 2-dependent myeloproliferative neoplasms in mice and humans

K. Ross, M. Gönen, J. Bradner, 2018 .

Corrigendum: Gene expression–based high-throughput screening (GE-HTS) and application to leukemia differentiation